Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2022.
Financials
Financial year 2025
KITOZYME from Herstal, company number BE0473676932, closed financial year 2025 with a result of € 824,661 after tax. For that financial year KITOZYME recorded revenue of € 7.1 million and equity of € 17.2 million. Compared with financial year 2024, the result moved from € 1.1 million to € 824,661. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 17.2 million
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 824,661
▼ 25% vs 2024
Profit after tax over the fiscal year.
€ 635,010
▼ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 8 million.
People and assets in 2025
27.2
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 2.8 million
▲ 7% vs 2024
€ 103,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 19,026
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.9 million
▼ 8% vs 2024
€ 1.7 million is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 249,077
▼ 48% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 842,533
▲ 9% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 7,696,097 | € 6,840,054 | € 6,670,868 | € 7,094,305 | ▲ 6% |
| Gross margin | € 4,874,587 | € 4,306,310 | € 4,497,749 | € 4,818,008 | ▲ 7% |
| Profit after taxes | € 1,532,381 | € 1,230,523 | € 1,097,523 | € 824,661 | ▼ 25% |
| Equity | € 13,764,557 | € 15,032,821 | € 16,014,844 | € 17,203,253 | ▲ 7% |
| Total debts | € 4,782,598 | € 4,146,493 | € 4,670,167 | € 4,840,008 | ▲ 4% |
| Cash | € 1,587,974 | € 533,599 | € 1,334,139 | € 635,010 | ▼ 52% |
| Land & buildings | € 0 | € 876,108 | € 795,941 | € 715,774 | ▼ 10% |
| Retained profit | € 4,853,609 | € 6,084,132 | € 7,181,655 | € 8,006,316 | ▲ 11% |
| Bank debt | € 2,912,301 | € 2,512,128 | € 3,097,698 | € 2,863,667 | ▼ 8% |
| Balance sheet total | € 18,798,910 | € 19,620,467 | € 21,043,801 | € 22,369,385 | ▲ 6% |
| Employees (FTE) | 30.5 | 28.2 | 27.3 | 27.2 | ▼ 0.1 |
Key figures of KITOZYME, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KITOZYME?
What happened at KITOZYME in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- P&L EAGLE srl stepped down as director. NBB
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 824,661 (▼ 25% vs 2024). Source: NBB ↗
- Carl MESTDAGH stepped down as director. NBB
- AMNASSEN srl stepped down as director. NBB
- P&L EAGLE srl became a director. NBB
- NOSHAQ PARTNERS SCRL became a director. NBB
In short
From € 1.5 million profit in 2022 to € 824,661 profit in 2025.
Best year ever: 2022, with € 1.5 million profit.
On average € 177,100 of value added per employee in 2025.
A new publication or filing at KITOZYME? We notify you, reason included.
Follow KITOZYMEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Wallonie Entreprendre comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
KITOZYMEThe shares are held by Valois sa (44%), Wallonie Entreprendre sa (18%), Innode SA (16%) and Wallonie Entreprendre (18.5%). It owns 75.9% of BIOKURIS sa and 20% of KIOMED PHARMA sa itself.
Directors
According to the 2025 annual accounts
Carl MESTDAGH
Chairman of the board
since 2020 · until 2026
since 2025 · until 2027
Director · represented by Benoit FELLIN
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2025 · until 2027
Managing director · represented by François BLONDEL
Also active at: Trafal Belgium, CETIM Student RE
since 2020 · until 2026
Director · represented by Géry LEFEBVRE
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International, Ateliers Pierre Cerfontaine, Floridienne, Fonderies J. Marichal Ketin et Cie, JUNGLING, MEBF +224 more
since 2025 · until 2027
Shareholders
Participations
75.9%
20%
Establishments
Establishment units
Physical locations of this company
Rue de Milmort 680
4040 Herstal
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0473.676.932
- VAT number
- BE 0473.676.932
- Registered office
- Rue de Milmort 680, 4040 Herstal
- Names & denominations
- KITOZYME
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 2 January 2001
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Vervaardiging van andere organische chemische basisproducten
Vervaardiging van overige organische chemische basisproducten